Equities

Daito Pharmaceutical Co Ltd

Daito Pharmaceutical Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (JPY)2,226.00
  • Today's Change45.00 / 2.06%
  • Shares traded47.60k
  • 1 Year change+6.32%
  • Beta0.8001
Data delayed at least 20 minutes, as of May 31 2024 07:00 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Daito Pharmaceutical Co., Ltd. is a Japan-based company mainly engaged in the pharmaceutical ingredients and formulation business, as well as healthy food. The pharmaceutical ingredients business is engaged in the manufacture, purchase, sale and entrusted manufacture business of pharmaceutical ingredients used as raw materials for pharmaceutical manufacture and formulation. The formulation business is engaged in the manufacture, purchase, sale and entrusted manufacture business of prescription pharmaceuticals and pharmaceuticals for general-use medicines.

  • Revenue in JPY (TTM)45.19bn
  • Net income in JPY3.28bn
  • Incorporated1942
  • Employees1.01k
  • Location
    Daito Pharmaceutical Co Ltd326, Yoka-machiTOYAMA-SHI 939-8567JapanJPN
  • Phone+81 764215665
  • Fax+81 764216006
  • Websitehttps://www.daitonet.co.jp/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
TAIKO PHARMACEUTICAL CO LTD6.33bn-2.90bn18.63bn208.00--2.49--2.94-58.49-58.49129.20148.040.4622.043.4430,432,690.00-21.14---26.00--44.27---45.75--2.92--0.2811--21.43--26.23------
Astena Holdings Co Ltd52.63bn1.62bn19.79bn1.40k11.790.66865.150.376140.9840.981,332.61722.460.81273.312.7637,482,540.002.492.494.444.4432.2725.333.062.320.8713--0.351744.924.73-2.85100.61-3.8538.5411.38
Medical Data Vision Co Ltd6.25bn688.02m21.25bn262.0029.485.0928.113.4018.0118.01163.57104.341.15282.077.8423,847,790.0012.1816.1617.0120.8877.4381.9010.5515.522.7213.480.0019.985.1512.4012.4869.75-23.95--
Fuso Pharmaceutical Industries Ltd55.41bn1.38bn21.73bn1.31k14.390.53587.580.3922159.77159.776,435.264,290.490.74743.122.43--1.861.913.063.0924.9826.922.492.691.0454.560.257641.178.613.76-14.219.029.13-2.64
Pharma Foods International Co., Ltd.65.08bn4.76bn25.47bn670.005.302.674.740.3914165.17165.172,257.80327.801.842.2212.7197,135,820.0013.448.4048.1219.2079.8981.347.323.850.844991.330.683928.2613.9453.90923.8057.9251.63--
Koa Shoji Holdings Co Ltd22.67bn2.87bn28.41bn297.009.901.257.931.2572.4572.45572.11573.530.78785.562.6276,317,420.009.987.9112.089.9329.9528.7412.6610.483.8636.550.114219.648.358.2713.9029.60-21.2615.52
StemRIM Inc2.35bn179.40m28.48bn44.00135.252.90--12.12-0.1097-0.109737.43159.710.2453----53,409,090.001.87-6.711.89-6.83----7.63-45.8078.90652.720.00--10,128.0663.68108.64------
Mizuho Medy Co Ltd11.34bn4.00bn32.77bn180.008.202.147.822.89419.74419.741,190.621,607.770.64841.872.9962,999,830.0022.8631.4626.2339.7873.4174.8535.2533.646.41--0.0034.83-37.4911.34-51.8532.64-17.7432.85
SanBio Co Ltd0.00-2.64bn34.73bn29.00--12.31-----40.50-40.500.0041.110.00----0.00-43.74-42.00-52.38-48.88-------4,790.72----0.1923------52.44--53.94--
Daito Pharmaceutical Co Ltd45.19bn3.28bn34.94bn1.01k10.710.67215.140.7732207.85207.852,864.813,311.810.61931.812.6544,701,280.004.356.995.649.2921.3822.717.038.831.15--0.123117.083.772.49-22.883.437.4812.70
Fuji Pharma Co Ltd43.05bn5.92bn36.76bn1.62k6.100.81943.990.8538243.57243.571,771.381,812.380.50711.343.2126,558,910.006.974.1010.565.5839.7842.4113.757.550.5895--0.382631.1715.421.5227.410.370919.045.73
Cuorips Inc23.10m-632.18m40.08bn46.00--6.69--1,734.90-86.04-86.043.14752.260.00474.6617.57---12.94---13.30--41.69---2,736.49--33.80-------39.65---39.84------
Seikagaku Corp36.21bn2.19bn44.71bn976.0019.640.59411.481.2340.0840.08663.801,324.810.46012.065.02--2.780.42613.050.467846.6054.186.040.98144.47--0.0055415.528.244.99-2.24-0.522430.280.00
Data as of May 31 2024. Currency figures normalised to Daito Pharmaceutical Co Ltd's reporting currency: Japanese Yen JPY

Institutional shareholders

32.44%Per cent of shares held by top holders
HolderShares% Held
Kaname Capital LP (Investment Management)as of 25 Apr 20241.23m7.84%
MFS International Singapore Pte Ltd.as of 31 Mar 2024696.19k4.44%
Highclere International Investors LLPas of 07 Jul 2023628.87k4.01%
Sumitomo Mitsui Trust Asset Management Co., Ltd.as of 31 May 2023510.84k3.25%
Nomura Asset Management Co., Ltd.as of 30 Apr 2024469.29k2.99%
The Vanguard Group, Inc.as of 09 May 2024445.98k2.84%
Dimensional Fund Advisors LPas of 09 May 2024316.97k2.02%
Portfolia, Inc.as of 31 Mar 2023312.95k1.99%
Kuwait Investment Authority (Investment Management)as of 31 May 2023258.83k1.65%
Ichiyoshi Asset Management Co., Ltd.as of 29 Jun 2022221.10k1.41%
More ▼
Data from 19 Dec 2022 - 23 May 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.